CA3236338A1 - Method of treating amyotrophic lateral sclerosis and dosing regimen for same - Google Patents

Method of treating amyotrophic lateral sclerosis and dosing regimen for same Download PDF

Info

Publication number
CA3236338A1
CA3236338A1 CA3236338A CA3236338A CA3236338A1 CA 3236338 A1 CA3236338 A1 CA 3236338A1 CA 3236338 A CA3236338 A CA 3236338A CA 3236338 A CA3236338 A CA 3236338A CA 3236338 A1 CA3236338 A1 CA 3236338A1
Authority
CA
Canada
Prior art keywords
patient
als
fasudil
treatment
treatment phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3236338A
Other languages
English (en)
French (fr)
Inventor
Thomas Macallister
Sven Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Woolsey Pharmaceuticals Inc
Original Assignee
Woolsey Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woolsey Pharmaceuticals Inc filed Critical Woolsey Pharmaceuticals Inc
Publication of CA3236338A1 publication Critical patent/CA3236338A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3236338A 2021-11-12 2022-11-10 Method of treating amyotrophic lateral sclerosis and dosing regimen for same Pending CA3236338A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163278523P 2021-11-12 2021-11-12
US63/278,523 2021-11-12
PCT/US2022/049541 WO2023086468A1 (en) 2021-11-12 2022-11-10 Method of treating amyotrophic lateral sclerosis and dosing regimen for same

Publications (1)

Publication Number Publication Date
CA3236338A1 true CA3236338A1 (en) 2023-05-19

Family

ID=86336738

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3236338A Pending CA3236338A1 (en) 2021-11-12 2022-11-10 Method of treating amyotrophic lateral sclerosis and dosing regimen for same

Country Status (7)

Country Link
US (1) US20240415846A1 (https=)
EP (1) EP4429667A4 (https=)
JP (1) JP2024543347A (https=)
CN (1) CN118251226A (https=)
CA (1) CA3236338A1 (https=)
MX (1) MX2024005745A (https=)
WO (1) WO2023086468A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025207476A1 (en) * 2024-03-25 2025-10-02 Woolsey Pharmaceuticals, Inc. Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007050783A2 (en) * 2005-10-26 2007-05-03 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US9980972B2 (en) * 2012-03-12 2018-05-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Rho kinase inhibitors for use in treating familial amyotrophic lateral sclerosis
US20180055887A1 (en) * 2016-08-23 2018-03-01 Academia Sinica Method for preparing induced mesenchymal stem cells and improving mesenchymal stem cell's characters and its applications
US11642352B2 (en) * 2020-03-25 2023-05-09 Woolsey Pharmaceuticals, Inc. Methods of treating wandering in Lewy dody dementia

Also Published As

Publication number Publication date
CN118251226A (zh) 2024-06-25
EP4429667A1 (en) 2024-09-18
US20240415846A1 (en) 2024-12-19
MX2024005745A (es) 2024-05-28
WO2023086468A1 (en) 2023-05-19
JP2024543347A (ja) 2024-11-21
EP4429667A4 (en) 2025-09-17

Similar Documents

Publication Publication Date Title
US20260098052A1 (en) Human aminosterol ent-03 compounds, related compositions comprising the same, and methods of using the same
US20250228868A1 (en) Method of treating amyotrophic lateral sclerosis
CA3175183A1 (en) Methods of using rho kinase inhibitors to treat alzheimer's disease
CA3236338A1 (en) Method of treating amyotrophic lateral sclerosis and dosing regimen for same
US20250381197A1 (en) Regimen for Treating Amyotrophic Lateral Sclerosis Having Onset 24 Months Prior to Treatment
MX2015001888A (es) Laquinimod para tratamiento de trastornos mediados por ácido gamma-aminobutírico.
US20260014167A1 (en) Treating Amyotrophic Lateral Sclerosis Having Onset 24 Months Prior to Treatment
US20240423997A1 (en) Method of treating amyotrophic lateral sclerosis
WO2024081763A1 (en) Method of treating amyotrophic lateral sclerosis by oral administration of fasudil
WO2025160116A1 (en) Methods of treating amyotrophic lateral sclerosis by oral administration of fasudil
US20240009180A1 (en) Medicine for alleviating neuropathic pain
US20230390232A1 (en) N-propargylglycine: a unique inhibitor of proline dehydrogenase with brain-enhancing mitohormesis properties capable of mitigating the pathogenesis of neurodegenerative disorders
WO2025207476A1 (en) Methods for treating als with a rho kinase inhibitor based on use of neurofilament light chain biomarker
AU2020324937B2 (en) Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
US20160151316A1 (en) Method of treating tourette's disorder with gaba-aminotransferase inactivators
WO2025240562A1 (en) Method of treating amyotrophic lateral sclerosis with trimetazidine
EP2961404B1 (en) Compositions and methods for treating amyotrophic lateral sclerosis in responders
HK40094114A (en) Medicine for alleviating neuropathic pain
CN117813095A (zh) 用于治疗肌萎缩侧索硬化症的vcp抑制剂
US20230310447A1 (en) Methods of treating age-related cognitive decline
Robberecht et al. Amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL

Year of fee payment: 2

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - SMALL

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251104

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251114

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251114

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251217

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260127

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260127

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260127

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260128